title: Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas.
abstract: CONCLUSIONS
  Concomitant antiemetic therapy comprising fosaprepitant, palonosetron, and dexamethasone is effective for head and neck carcinoma.
  
  
  OBJECTIVE
  A patient diary was constructed to determine the effectiveness of concomitant antiemetic therapy with a neurokinin-1 receptor antagonist (fosaprepitant), 5-hydroxytryptamine receptor antagonist (palonosetron), and dexamethasone in accordance with guidelines.
  
  
  METHODS
  Subjects comprised 41 patients who received 71 courses of chemotherapy, along with fosaprepitant, palonosetron, and dexamethasone. A patient diary was compiled concerning the presence/absence of vomiting, vomiting episodes, presence/absence of rescue therapy, food intake, presence/absence of nausea, and general condition.
  
  
  RESULTS
  The frequency of the primary end point of complete response in the overall phase was 69.0%. The proportion of patients with no vomiting in the overall phase was 90.1%. In the acute phase, the proportion of no nausea and slight nausea together was 91.5%, no change in and slightly reduced food intake together was 87.3%, and the proportion of good general condition and relatively good general condition was 85.9%. In the delayed phase, the proportion of no nausea and slight nausea together was 56.3%, no change in and slightly reduced food intake together was 43.7%, and the proportion of good general condition and relatively good general condition together was 53.5%.
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center , Tokyo.
authors.forename: Kiyoaki
authors.initials: K
authors.lastname: Tsukahara
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nakamura
authors.forename: Ray
authors.initials: R
authors.lastname: Motohashi
authors.forename: Hiroki
authors.initials: H
authors.lastname: Sato
authors.forename: Minoru
authors.initials: M
authors.lastname: Endo
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Katsube
authors.forename: Yuri
authors.initials: Y
authors.lastname: Ueda
authors.forename: Mamoru
authors.initials: M
authors.lastname: Suzuki
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002277:Carcinoma / Q000188:drug therapy*; D002945:Cisplatin / Q000009:adverse effects*; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004435:Eating / Q000187:drug effects; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000494:pharmacology / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D064729:Neurokinin-1 Receptor Antagonists / Q000627:therapeutic use; D000077924:Palonosetron; D011812:Quinuclidines / Q000494:pharmacology / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D007546:Isoquinolines; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D011812:Quinuclidines; D012702:Serotonin Antagonists; D000077924:Palonosetron; C579707:fosaprepitant; D003907:Dexamethasone; D002945:Cisplatin
keywords: CINV; Chemotherapy-induced nausea and vomiting; aprepitant; food intake; rescue therapy